BridgeBio Pharma, Inc. (BBIO): Capital Expenditures
$1.10M
Year ended 2025-12-31
$1.01M
Trailing 12 months to 2026-06-30
-38.9%
3-year compound annual growth
-32.0%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.10M | +17.6% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $933.0K | -28.6% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $1.31M | -72.9% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $4.82M | -63.6% | 2025-02-20, From 2022-01-01 |
| 2021-12-31 | $13.25M | +76.2% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $7.52M | +185.0% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $2.64M | +21.1% | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | $2.18M | +369.4% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $464.0K | n/a | 2020-03-03, From 2017-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $1.10M | +17.6% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $954.0K | -3.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $6.48M | -40.9% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $14.15M | -21.1% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $8.10M | +43.2% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $14.15M | +41.1% |
| Insmed Inc (INSM) | 2025-12-31 | $32.56M | +48.5% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $12.28M | -50.9% |
| Innoviva, Inc. (INVA) | 2025-12-31 | $1.13M | +318.9% |
Compare BBIO, MIRM, NATR, HCM side by side · Screen every company in Pharmaceutical Preparations ↗